NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
Cited by 956 works. doi:10.6004/jnccn.2019.0059 Open-access PDF
Authors
- David S. Ettinger
- Douglas E. Wood
- Charu Aggarwal
- Dara L. Aisner
- Wallace Akerley
- Jessica Ruth Bauman
- Ankit Bharat
- Débora S. Bruno
- Joe Yujiao Chang
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Thomas J. Dilling
- M.C. Dobelbower
- Scott N. Gettinger
- Ramaswamy Govindan
- Matthew A. Gubens
- Mark W. Hennon
- Leora Horn
- Rudy P. Lackner
- Michael D. Lanuti
References
- Cancer statistics, 2019
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater